Teva earns FDA approval for 2 new asthma inhaler drugs

The Food and Drug Administration approved Teva Pharmaceuticals’ two new asthma products, the AirDuo RespiClick and the ArmonAir RespiClick.

Advertisement

Both products deliver dry powder asthma medication through Teva’s RespiClick inhaler.

The AirDuo RespiClick contains the same active ingredients as GlaxoSmithKline’s inhaler drug Advair, while the ArmonAir RespiClick contains the same active ingredients as GSK’s other asthma drug Flovent. Both inhalers are intended to treat asthma in adults 12 years and older.

Teva expects both products to be available in the U.S. later this year.

More articles on supply chain:

Target launches new guidelines to control chemicals in its supply chain
Shark antibodies could successfully transport drugs to brain
Mylan CEO speaks out for 1st time since congressional hearing: 5 quotes

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.